Abbott Laboratories (ABT) Short-Term Debt issuances (2009 - 2026)

Abbott Laboratories has reported Short-Term Debt issuances for 18 years, with the latest figure at $64.0 million in Q2 2026.

• Quarterly Short-Term Debt issuances rose 500.0% year-over-year to $64.0 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $32.0 million (up 77.78% YoY) and the FY2025 annual result came in at -$115.0 million, down 15.0% from the prior year.
• Short-Term Debt issuances improved to $64.0 million in Q2 2026 per ABT's latest filing, from $31.0 million in the prior quarter.
• Over five years, Short-Term Debt issuances peaked at $111.0 million in Q4 2023 and troughed at -$127.0 million in Q1 2024.
• A 5-year average of -$2.9 million and a median of $8.0 million in 2022 frame the typical range for Short-Term Debt issuances.
• The widest YoY moves for Short-Term Debt issuances: up 1010.0% in 2023, down 625.0% in 2023.
• Over 5 years, Short-Term Debt issuances stood at $10.0 million in 2022, then jumped by 1010.0% to $111.0 million in 2023, then sank by 76.58% to $26.0 million in 2024, then tumbled by 373.08% to -$71.0 million in 2025, then jumped by 190.14% to $64.0 million in 2026.
• According to Business Quant data, Short-Term Debt issuances over the past three periods registered $64.0 million, $31.0 million, and -$71.0 million for Q2 2026, Q1 2026, and Q4 2025 respectively.